Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1126/scitranslmed.aaa5079 http://scihub22266oqcxt.onion/10.1126/scitranslmed.aaa5079 C4807901!4807901!26109102     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Transl+Med 2015 ; 7 (293): 293ra102 Nephropedia Template TP {{tp|p=26109102|t=2015. Epigenetic therapy overcomes treatment resistance in T-cell prolymphocytic leukemia |pdf=|usr=}}{{26109102}} gab.com Text Epigenetic therapy overcomes treatment resistance in T-cell prolymphocytic leukemia JO: Sci Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=26109102 #FOAvip T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with distinct features and an aggressive clinical course. Early relapse and short overall survival are commonplace. Use of the monoclonal anti-CD52 antibody alemtuzumab has improved the rate of complete remission and duration of response to over 50% and between 6?12 months, respectively. Despite this advance, without an allogeneic transplant, resistant relapse is inevitable. We report complete (7) and partial (1) remissions in eight patients receiving alemtuzumab and cladribine with or without an HDAC inhibitor. These data show that administration of epigenetic agents overcomes alemtuzumab resistance. We report epigenetically induced expression of the surface receptor protein CD30 in T-PLL. Subsequent treatment with the anti-CD30 antibody drug conjugate brentuximab vedotin overcame organ specific (skin) resistance to alemtuzumab. Our findings demonstrate activity of combination epigenetic and immunotherapy in the incurable illness T-PLL, particularly in the setting of prior alemtuzumab therapy. Twit Text FOAVip Epigenetic therapy overcomes treatment resistance in T-cell prolymphocytic leukemia ????Sci Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=26109102 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26109102 #FOAvip English Wikipedia <ref>{{Cite pmid|26109102}}</ref> Epigenetic therapy overcomes treatment resistance in T-cell prolymphocytic leukemia #MMPMID26109102 Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Shah MV; Sharma K; Leshchenko VV; Parekh S; Loughran T; Epner E Sci Transl Med 2015[Jun]; 7 (293): 293ra102 PMID26109102show ga T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with distinct features and an aggressive clinical course. Early relapse and short overall survival are commonplace. Use of the monoclonal anti-CD52 antibody alemtuzumab has improved the rate of complete remission and duration of response to over 50% and between 6?12 months, respectively. Despite this advance, without an allogeneic transplant, resistant relapse is inevitable. We report complete (7) and partial (1) remissions in eight patients receiving alemtuzumab and cladribine with or without an HDAC inhibitor. These data show that administration of epigenetic agents overcomes alemtuzumab resistance. We report epigenetically induced expression of the surface receptor protein CD30 in T-PLL. Subsequent treatment with the anti-CD30 antibody drug conjugate brentuximab vedotin overcame organ specific (skin) resistance to alemtuzumab. Our findings demonstrate activity of combination epigenetic and immunotherapy in the incurable illness T-PLL, particularly in the setting of prior alemtuzumab therapy. äEpigenetic therapy overcomes treatment resistance in T-cell prolymphoc(epmc).pdf DeepDyve Pubget Overpricing